Abstracts tagged "fibromyalgia"

Abstract Number: 1879 • 2012 ACR/ARHP Annual Meeting
Work Related Injuries Causing or Aggravating Fibromyalgia in the Medicolegal Arena: A Jurisprudential Analysis
Mary-Ann Fitzcharles¹, Peter A. Ste-Marie² and Yoram Shir³, ¹Rheumatology and Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ²University of Montreal, Montreal, QC, Canada, ³Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Up to 40% of persons report onset of fibromyalgia (FM) following a “triggering event”. Injuries, which may occur in the workplace, may be implicated…
Abstract Number: 960 • 2012 ACR/ARHP Annual Meeting
Cyclobenzaprine (CBP) and Its Major Metabolite Norcyclobenzaprine (nCBP) Are Potent Antagonists of Human Serotonin Receptor 2a (5HT2a), Histamine Receptor H-1 and á-Adrenergic Receptors: Mechanistic and Safety Implications for Treating Fibromyalgia Syndrome by Improving Sleep Quality
Bruce Daugherty, Leland Gershell and Seth Lederman, Research and Development, Tonix Pharmaceuticals, Inc., New York, NY
Background/Purpose: Bedtime cyclobenzaprine (CBP) improves fibromyalgia symptoms (pain, fatigue, tenderness, and mood) and improves sleep quality (decreases Cyclic Alternating Pattern Type A2 + A3) (1).…
Abstract Number: 1881 • 2012 ACR/ARHP Annual Meeting
Increased Psychosocial Stress Is a Major Component of Fibromyalgia Triggers
Emma K. Guymer¹, Kathleen Elford² and Geoffrey O. Littlejohn³, ¹Rheumatology and Medicine, Monash Medical Centre and Monash University, Clayton, Victoria, Australia, ²Rheumatology, Monash Medical Centre, Clayton, Victoria, Australia, ³Rheumatology, Monash Medical Centre and Monash University, Clayton, VIC, Australia
Background/Purpose: Fibromyalgia is a common, chronic pain disorder. Initial development of symptoms occurs under conditions unique to each patient. Psychological and physical triggers are recognized,…
Abstract Number: 963 • 2012 ACR/ARHP Annual Meeting
Efficacy of Long-Term Milnacipran Treatment in Patients Meeting Different Thresholds of Clinically Relevant Pain Relief: Subgroup Analysis of a Double-Blind, Placebo-Controlled Discontinuation Study
Daniel J. Clauw¹, Philip J. Mease², Robert H. Palmer³, Joel M. Trugman⁴ and Yimin Ma⁴, ¹Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Forest Research Institute, Inc., Jersey City, NJ, ⁴Forest Research Institute, Jersey City, NJ
Background/Purpose: Patients with fibromyalgia (FM) who received up to 3.25 years of milnacipran (MLN) in a flexible-dose (≤200 mg/d) open-label (OL) study were eligible to…
Abstract Number: 1882 • 2012 ACR/ARHP Annual Meeting
Predictors of a Favorable Outcome in Patients with Fibromyalgia: Results From the 1-Year Follow-up
Dong-Jin Park¹, Shin-Seok Lee², Seong-Ho Kim³, Seong-Su Nah⁴, Ji Hyun Lee⁵, Seong-Kyu Kim⁶, Yeon-Ah Lee⁷, Seung-Jae Hong⁷, Hyun-Sook Kim⁸, Hye-Soon Lee⁹, Hyoun Ah Kim¹⁰, Chung-Il Joung¹¹ and Sang-Hyon Kim¹², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ³Department of Internal Medicine,, Inje University Haeundae Paik Hospital, Busan, South Korea, ⁴Rheumatology, Soonchunhyang University, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Maryknoll Medical Center, Busan, South Korea, ⁶Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁸Internal Medicine, Chosun University Hospital, Gwangju, South Korea, ⁹Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹⁰Ajou University Hospital, Suwon, South Korea, ¹¹Department of Internal Medicine, Konyang university hospital, Daejeon, South Korea, ¹²Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea
Background/Purpose: To determine the outcomes in Korean patients with fibromyalgia (FM) and identify the prognostic factors associated with improvement at 1-year follow-up. Methods: Forty-eight patients…
Abstract Number: 967 • 2012 ACR/ARHP Annual Meeting
Haplotypes of GTP Cyclophydrolase Gene Polymorphisms Are Protective in the Susceptibility of Fibromyalgia Syndrome
Hwajeong Lee¹, Shin-Seok Lee², Seong-Kyu Kim³, Jung-Yoon Choe⁴, Seong-Ho Kim KIM⁵, Seong-Su Nah⁶, Ji Hyun Lee⁷, Seung-Jae Hong⁸, Hyun-Sook Kim⁹, Hye-Soon Lee¹⁰, Hyun Ah Kim¹¹ and Chung-Il Joung¹², ¹Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ³Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁵Department of Internal Medicine,, Inje University Haeundae Paik Hospital, Busan, South Korea, ⁶Department of Internal Medicine, Soonchunhyang University, College of Medicine, Cheonan, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Maryknoll Medical Center, Busan, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁹Internal Medicine, Chosun University Hospital, Gwangju, South Korea, ¹⁰Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹¹Division of Rheumatology, Department of Internal Medicine, Hallym university, Kyunggi, South Korea, ¹²Department of Internal Medicine, Konyang university hospital, Daejeon, South Korea
Background/Purpose: Guanosine triphosphate cyclohydrolase 1 (GCH1) is the rate-limiting enzyme in the synthesis of tetrahydrobiopterin, which is an essential co-factor in nitric oxide (NO) production.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].